Clinical trial Recruiting at 1 site Observational Ages 18 and up

Observing IBD patients with fatty liver disease

Official title: A Bidirectional, Multicenter Cohort Study of Inflammatory Bowel Disease (IBD) Patients With Nonalcoholic Fatty Liver Disease (NAFLD)

Run by Shanghai East Hospital · NCT06939569 · Data updated 2026-11-12

This study looks at people with inflammatory bowel disease to see how common fatty liver disease is among them and how it affects their overall health.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment337 (estimated)
SponsorShanghai East Hospital
Academic / other
Locations1 site (Shanghai)
StatusRecruiting
StartedMay 1, 2025
Main results expectedDecember 1, 2027
Study endsDecember 1, 2027
Registry record updatedApril 23, 2025
Trial IDNCT06939569 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults over 18 years old diagnosed with inflammatory bowel disease.

Probably not a fit

Patients with incomplete clinical data or severe comorbidities may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients with inflammatory bowel disease (IBD) and examines the prevalence and impact of non-alcoholic fatty liver disease (NAFLD) among them. It aims to identify the similarities and differences between IBD patients with and without NAFLD, as well as to assess how the presence and severity of NAFLD may influence the clinical outcomes of IBD. The study will utilize a cohort of previously established IBD patients to gather relevant clinical data and insights.

Why it matters

Potential benefit: If successful, this study could enhance understanding of the relationship between IBD and NAFLD, leading to improved management strategies for affected patients.

How similar studies have gone: There have been no relevant studies to date that specifically address the relationship between IBD and NAFLD, making this approach novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Subjects aged over 18 years (including borderline values), of either sex.
2. Subjects consistented with the Chinese consensus on the diagnosis and treatment of IBD;
3. Subjects able to cooperate with follow-up, participate in this study and sign the informed consent.

Exclusion Criteria:

1. Subjects with incomplete clinical data;
2. Subjects can not to cooperate with follow-up, and refuse to sign the informed consent;
3. Subjects can not to cooperate with the completion of relevant examinations; 4 Pregnant women;

5.Subjects with severe heart, lung, kidney and other organ diseases or cancer, and expected survival time less than 6 months.

Where it's running

  • Shanghai East Hospital
    Shanghai, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.